Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Intermittent claudication; Ischaemic heart disease; Prevention of thrombotic stroke >18 yr: 250 mg twice daily. Prevention of subacute stent occlusion after intracoronary stenting >18 yr: 250 mg twice daily for 4 wk, w/ aspirin, starting at the time of stent placement.
Dosage Details
Prophylaxis of subacute stent occlusion after intracoronary stenting
Adult: >18 yr: 250 mg bid for 4 wk, in conjunction with aspirin, starting at the time of stent placement.

Prophylaxis of thrombotic stroke, Ischaemic heart disease, Intermittent claudication
Adult: >18 yr: 250 mg bid.
Renal Impairment
Dose reduction or discontinuance if haemorrhagic or haematopoietic complications occur.
Hepatic Impairment
Severe: contraindicated.
Should be taken with food.
Pre-existing or history of blood dyscrasias; haemostatic disorder or active pathological bleeding (eg. bleeding peptic ulcer, intracranial bleeding); severe hepatic dysfunction. Hypersensitivity. Lactation.
Special Precautions
Patients with increased risk of bleeding from trauma, surgery or pathological disorder. Moderate to severe renal impairment. May need to stop therapy 10-14 days before elective surgery. Full blood counts should be performed prior to therapy and every 2 wk during the first 3 mth of treatment. Pregnancy.
Adverse Reactions
Diarrhoea, nausea, dyspepsia, bleeding, pupura, skin rash, increase in serum cholesterol concentration, elevation of LFTs, hepatitis, cholestatic jaundice.
Potentially Fatal: Neutropenia, agranulocytosis, thrombotic thrombocytopenic purpura and aplastic anaemia.
GI haemorrhage, convulsions, hypothermia, dyspnoea, loss of equilibrium and abnormal gait.
Drug Interactions
Reduced clearance with cimetidine; corticosteroid may antagonise effects on bleeding time. Avoid concurrent use with clopidogrel.
Potentially Fatal: Risk of haemorrhage increased with NSAIDs and oral anticoagulants; decreased metabolism of theophylline, phenytoin and bupropion.
Food Interaction
Increased risk of bleeding with Ginkgo biloba and Kangen-karyu.
Description: Ticlopidine inhibits adenosine diphosphate-mediated platelet aggregation.
Absorption: Rapidly and almost completely absorbed from the GI tract (oral). Oral bioavailability increased by 20% when taken after meals.
Distribution: Protein-binding: Extensive.
Metabolism: Hepatic: Extensive.
Excretion: As metabolites; via urine (60%), via faeces (25%). Terminal half-life: 30-50 hr.
Disclaimer: This information is independently developed by MIMS based on Ticlopidine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in